Semaglutide & Tirzepatide: Eye Disorder Risk Increase
- patients with type 2 diabetes (T2D) taking the medications semaglutide or tirzepatide may have a slightly elevated risk of developing certain optic nerve disorders, including nonarteritic anterior ischemic...
- NAION is the most common cause of acute optic nerve injury in adults over the age of 50.
- Researchers conducted a comprehensive cohort study using a large,nationwide database of US electronic health records (EHRs) spanning from December 2017 to January 2023.
New Study Links Diabetes Drugs to Slight Increase in Optic Nerve Issues
Table of Contents
Published August 18, 2025
The Connection Between Semaglutide, Tirzepatide, and Vision
patients with type 2 diabetes (T2D) taking the medications semaglutide or tirzepatide may have a slightly elevated risk of developing certain optic nerve disorders, including nonarteritic anterior ischemic optic neuropathy (NAION), according to a recent study published in JAMA Network Open. While the overall risk remains low, the findings highlight the importance of vigilance regarding potential vision changes in individuals using thes increasingly popular drugs.
Understanding NAION and It’s Impact
NAION is the most common cause of acute optic nerve injury in adults over the age of 50. It’s characterized by a sudden, painless loss of vision, and while its exact cause isn’t fully understood, it can be debilitating. According to the american Academy of Ophthalmology, the annual incidence of NAION is estimated between 2.3 to 10.2 cases per 100,000 people over 50, and 0.54 per 100,000 across all ages. The condition affects men and women equally, with White individuals experiencing a slightly higher risk.
How the Study Was Conducted
Researchers conducted a comprehensive cohort study using a large,nationwide database of US electronic health records (EHRs) spanning from December 2017 to January 2023. The study included over 1.5 million adults with type 2 diabetes who had no prior history of eye disorders. Participants were prescribed either semaglutide, tirzepatide, or other antidiabetic medications. To ensure a fair comparison, the researchers used a technique called propensity score matching, effectively creating two groups of nearly 159,400 patients with similar characteristics.
The primary focus was to track the occurrence of NAION and other optic nerve or visual pathway disorders over a two-year period.
Key Findings: A Modest Increase in Risk
The study revealed that patients taking semaglutide or tirzepatide had a higher incidence of optic nerve disorders compared to those on other diabetes medications. specifically:
- NAION: 35 patients (0.04%) in the semaglutide/tirzepatide group developed NAION, compared to 19 patients (0.02%) in the comparison group (hazard ratio [HR] 1.76; 95% confidence interval [CI] 1.01-3.07).
- Other Optic Nerve Disorders: 93 patients (0.12%) in the treatment group experienced other optic nerve disorders, compared to 54 patients (0.07%) in the control group (HR 1.65; 95% CI 1.18-2.31).
Importantly, the study did not find a significant link between semaglutide/tirzepatide and other optic nerve conditions like optic neuritis, papilledema, optic atrophy, or optic disc disorders.
| Outcome | Semaglutide/Tirzepatide Group | Comparison Group | Hazard Ratio (HR) | 95% Confidence Interval (CI) |
|---|---|---|---|---|
| NAION | 35 (0.04%) | 19 (0.02%) | 1.76 | 1.01-3.07 |
| Other Optic Nerve Disorders | 93 (0.12%) | 54 (0.07%) | 1.65 | 1.18-2.31 |
Significant Considerations and Limitations
The researchers acknowledge several limitations to their study. The reliance on retrospective EHR data introduces the possibility of unmeasured factors influencing the results. Additionally, the lack of a specific diagnostic code for NAION in the International Classification of Diseases, Tenth Revision could lead to inaccuracies in diagnosis. furthermore, the study couldn’t assess medication adherence, which could play a role.
It’s also important to note that the study population was limited to individuals within the TriNetX network, and the follow-up period was two years, potentially limiting the generalizability of the findings.
What Should You Do?
If you are taking semaglutide or tirzepatide for type 2 diabetes, it’s essential to be aware of the potential, though small, risk of optic nerve disorders.Report any sudden changes in vision,such as blurred vision,double vision,or vision loss,to your doctor promptly. regular eye exams are also crucial for early detection and management of any potential issues.